FBXO17

Across TCGA pan-cancer cohorts, FBXO17 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of FBXO17’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FBXO17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FBXO17 is over-expressed in tumor, although a few such as LSCC and OV show the opposite, repressed pattern.

CCRCC, LSCC, and OV are the cancer types where FBXO17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXO17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.694	<.001	9	view →
LSCC	Male	II,III,IV	−0.422	<.001	6	view →
OV	All	All	−1.789	.028	2	view →
PDAC	Male	All	−0.824	.001	2	view →
LUAD	All	All	−0.714	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

FBXO17–CCRCC

Open the CCRCC breakdown →